Medable Secures Another $78 Million Funding To Fuel Digital Innovation For Patient-Centered Drug Development
Medable Secures Another $78 Million Funding To Fuel Digital Innovation For Patient-Centered Drug Development
04/15/21, 11:45 AM
Location
palo altoMoney raised
$78 million
Medable Inc. today announced $78 million in new funding to fuel advances in the delivery of digital and decentralized clinical trials, accelerating the industry’s shift to patient-centered drug development. The funding was led by Sapphire Ventures, along with new investor Obvious Ventures and follow-on investment from existing investors GSR Ventures, PPD, Inc. (Nasdaq:PPD) and Streamlined Ventures.
Company Info
Location
palo alto, california, united states
Additional Info
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.